cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.5712160
title: Supplementary Material for: ICS Use May Modify FEV<sub>1</sub> Decline in α<sub>1</sub>-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils

description: <b><i>Background:</i></b> α<sub>1</sub>-Antitrypsin deficiency (AATD) predisposes to chronic obstructive pulmonary disease (COPD). In COPD unrelated to AATD, the role of a higher blood eosinophil count in disease and subsequent personalization of therapy has recently received much attention. We sought to investigate this concept in patients with AATD-associated COPD. <b><i>Objectives:</i></b> The study aims to evaluate eosinophilia status against outcomes including mortality and FEV<sub>1</sub> decline in patients with AATD. <b><i>Methods:</i></b> All patients with PiSZ and PiZZ genotypes were identified from the UK AATD registry. The participants were substratified according to inhaled corticosteroid (ICS) use. Blood eosinophil counts were assessed from baseline and annually during follow-up (range 1–18 years). Eosinophilia was defined as a level &gt;0.2 × 10<sup>9</sup>/L, and classified by the frequency of such counts into “always,” “intermittent,” or “never present.” Univariate and multivariate analyses were conducted. <b><i>Results:</i></b> In total, 646 participants were included, 53.9% of whom demonstrated intermittent and 7.4% persistent eosinophilia. Survival did not differ according to eosinophilic group (<i>p</i> &gt; 0.05). Those with persistent eosinophilia showed a slower FEV<sub>1</sub> decline (<i>p</i> &lt; 0.001). There was no clear association with exacerbation frequency. Patients on ICS at baseline were more likely to be eosinophilic (<i>p</i> = 0.002) and having a lower FEV<sub>1</sub> (<i>p</i> &lt; 0.001) and greater pack-year exposure (16.5 vs. 7.8 pack-years, <i>p</i> &lt; 0.001). When the multivariate analyses of FEV<sub>1</sub> decline were stratified for baseline ICS use, the association of persistent eosinophilia with slower decline persisted in those on ICS. <b><i>Conclusions:</i></b> Blood eosinophil levels persistently &gt;0.2 × 10<sup>9</sup>/L may be an indication for ICS use in PiZZ AATD in order to reduce FEV<sub>1</sub> decline.
DOI: 10.6084/m9.figshare.5712160.v1
title: Supplementary Material for: ICS Use May Modify FEV<sub>1</sub> Decline in α<sub>1</sub>-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils

description: <b><i>Background:</i></b> α<sub>1</sub>-Antitrypsin deficiency (AATD) predisposes to chronic obstructive pulmonary disease (COPD). In COPD unrelated to AATD, the role of a higher blood eosinophil count in disease and subsequent personalization of therapy has recently received much attention. We sought to investigate this concept in patients with AATD-associated COPD. <b><i>Objectives:</i></b> The study aims to evaluate eosinophilia status against outcomes including mortality and FEV<sub>1</sub> decline in patients with AATD. <b><i>Methods:</i></b> All patients with PiSZ and PiZZ genotypes were identified from the UK AATD registry. The participants were substratified according to inhaled corticosteroid (ICS) use. Blood eosinophil counts were assessed from baseline and annually during follow-up (range 1–18 years). Eosinophilia was defined as a level &gt;0.2 × 10<sup>9</sup>/L, and classified by the frequency of such counts into “always,” “intermittent,” or “never present.” Univariate and multivariate analyses were conducted. <b><i>Results:</i></b> In total, 646 participants were included, 53.9% of whom demonstrated intermittent and 7.4% persistent eosinophilia. Survival did not differ according to eosinophilic group (<i>p</i> &gt; 0.05). Those with persistent eosinophilia showed a slower FEV<sub>1</sub> decline (<i>p</i> &lt; 0.001). There was no clear association with exacerbation frequency. Patients on ICS at baseline were more likely to be eosinophilic (<i>p</i> = 0.002) and having a lower FEV<sub>1</sub> (<i>p</i> &lt; 0.001) and greater pack-year exposure (16.5 vs. 7.8 pack-years, <i>p</i> &lt; 0.001). When the multivariate analyses of FEV<sub>1</sub> decline were stratified for baseline ICS use, the association of persistent eosinophilia with slower decline persisted in those on ICS. <b><i>Conclusions:</i></b> Blood eosinophil levels persistently &gt;0.2 × 10<sup>9</sup>/L may be an indication for ICS use in PiZZ AATD in order to reduce FEV<sub>1</sub> decline.
DOI: 10.6084/m9.figshare.5712157
title: Tables

description: Tables
DOI: 10.6084/m9.figshare.5712157.v1
title: Tables

description: Tables
DOI: 10.6084/m9.figshare.5712148
title: Supplementary Files

description: Supplementary Files
DOI: 10.6084/m9.figshare.5712148.v1
title: Supplementary Files

description: Supplementary Files
DOI: 10.6084/m9.figshare.5712142
title: Supplementary Material for: Persistent Hemichorea and Caudate Atrophy in Untreated Diabetic Striatopathy: A Case Report

description: <b><i>Background:</i></b> Neurological complications of diabetes and hyperglycemia are relatively common but the specific manifestations can vary widely. Diabetic striatal disease or “diabetic striatopathy” is an uncommon condition usually thought to result from hyperglycemic injury to the basal ganglia, producing a hyperkinetic movement disorder, usually choreiform in nature. Symptoms are generally reversible with treatment of the hyperglycemia. <b><i>Case Description:</i></b> We report the case of a 57-year-old woman presenting with a unilateral choreoathetosis of the left upper extremity, persistent for 4 years. Contemporaneous imaging demonstrated severe atrophy of the right caudate nucleus, while imaging obtained at the onset of symptoms was consistent with a right diabetic striatopathy. Symptoms improved with the use of dopamine antagonists and benzodiazepines. <b><i>Conclusion:</i></b> Although generally considered to be fully reversible, this case demonstrates that diabetic striatopathy can result in permanent structural lesions with persistent symptoms if left untreated.
DOI: 10.6084/m9.figshare.5712142.v1
title: Supplementary Material for: Persistent Hemichorea and Caudate Atrophy in Untreated Diabetic Striatopathy: A Case Report

description: <b><i>Background:</i></b> Neurological complications of diabetes and hyperglycemia are relatively common but the specific manifestations can vary widely. Diabetic striatal disease or “diabetic striatopathy” is an uncommon condition usually thought to result from hyperglycemic injury to the basal ganglia, producing a hyperkinetic movement disorder, usually choreiform in nature. Symptoms are generally reversible with treatment of the hyperglycemia. <b><i>Case Description:</i></b> We report the case of a 57-year-old woman presenting with a unilateral choreoathetosis of the left upper extremity, persistent for 4 years. Contemporaneous imaging demonstrated severe atrophy of the right caudate nucleus, while imaging obtained at the onset of symptoms was consistent with a right diabetic striatopathy. Symptoms improved with the use of dopamine antagonists and benzodiazepines. <b><i>Conclusion:</i></b> Although generally considered to be fully reversible, this case demonstrates that diabetic striatopathy can result in permanent structural lesions with persistent symptoms if left untreated.
DOI: 10.6084/m9.figshare.5712139
title: Figures

description: Figures
DOI: 10.6084/m9.figshare.5712139.v1
title: Figures

description: Figures
DOI: 10.6084/m9.figshare.5712127
title: Data - crop biomass as a funcion of crop age - empirical data for perennial crops

description: Data on crop biomass (empirical values of biomass as a function of crop age) for different perennial crops used to parametrise the Perennial-GHG model. This model has been published and described in the paper "Perennial-GHG: A new generic allometric model to estimate biomass accumulation and greenhouse gas emissions in perennial food and bioenergy crops" by A. Ledo et al - Environmental Modelling and Software.
DOI: 10.6084/m9.figshare.5712124
title: recount.all.data.plier.RData

description: This is the PLIER model based on all human samples from recount2 database (https://jhubiostatistics.shinyapps.io/recount/). Gene expression is normalized by rpkm (Reads Per Kilobase Million).<br>
DOI: 10.6084/m9.figshare.5712124.v1
title: recount.all.data.plier.RData

description: This is the PLIER model based on all human samples from recount2 database<br>
DOI: 10.6084/m9.figshare.5712091
title: Oxford Screening of CSF and Respiratory Samples ('OSCAR'): interactive data visualisation using Krona to display results from a pilot project using Next Generation Sequencing (NGS) for identification of viruses from clinical laboratory samples

description: This is an html file that allows visualisation of metagenomic dataset from a pilot project to screen CSF and respiratory samples using Illumina HiSeq after completion of routine diagnostic testing in a UK microbiology laboratory.<br>Methods and underlying metadata are available through a separate DOI (10.6084/m9.figshare.5670007). The entire metagenomic dataset has been uploaded to the European Nucleotide Archive (primary accession PRJEB22949). A subset of these data have been used for a project to identify human herpesvirus 6 (HHV-6) in clinical samples; this manuscript is available on BioRxiv (https://doi.org/10.1101/236083).<br>This study was approved through the UK integrated research application system (REC reference 14/LO/1077).
DOI: 10.6084/m9.figshare.5712016
title: Supplementary Datasets for "The Primary Transcriptome of the Fast-Growing Cyanobacterium Synechococcus elongatus UTEX 2973"

description: This file set contains supplementary dataset for paper "Tan, X.<i> et al.</i> <b>The Primary Transcriptome of the Fast-Growing Cyanobacterium Synechococcus elongatus UTEX 2973</b>. (doi.org/10.1186/s13068-018-1215-8)." Please refer to this paper for more information.<b><br></b><b>File Description:</b><b><br></b><b>Supplementary Dataset 1:</b> Genome-wide visualization of predicted TSS and coverage for the genome of <i>Synechococcus elongatus </i>UTEX 2973.<b>Supplementary Dataset 2: </b>Genome annotation of <i>Synechococcus elongatus </i>UTEX 2973 with predicted TSS positions.<br><br><b>How To Cite This Dataset:</b><br>If you find this dataset useful to your research, please consider to cite the main paper:<br>Tan, X., Hou, S., Song, K., Georg, J., Klähn, S., Lu, X., & Hess, W. R. (2018). <b>The primary transcriptome of the fast-growing cyanobacterium <i>Synechococcus elongatus</i> UTEX 2973</b>. <i>Biotechnology for Biofuels</i>, <i>11</i>(1), 218.<br><br>
DOI: 10.6084/m9.figshare.5712016.v1
title: Supplementary Datasets for "The Primary Transcriptome of the Fast-Growing Cyanobacterium Synechococcus elongatus UTEX 2973"

description: This file set contains supplementary dataset for paper "Tan, X.<i> et al.</i> <b>The Primary Transcriptome of the Fast-Growing Cyanobacterium Synechococcus elongatus UTEX 2973</b>. (doi.org/10.1186/s13068-018-1215-8)." Please refer to this paper for more information.<b><br></b><b>File Description:</b><b><br></b><b>Supplementary Dataset 1:</b> Genome-wide visualization of predicted TSS and coverage for the genome of <i>Synechococcus elongatus </i>UTEX 2973.<b>Supplementary Dataset 2: </b>Genome annotation of <i>Synechococcus elongatus </i>UTEX 2973 with predicted TSS positions.<br><br><b>How To Cite This Dataset:</b><br>If you find this dataset useful to your research, please consider to cite the main paper:<br>Tan, X., Hou, S., Song, K., Georg, J., Klähn, S., Lu, X., & Hess, W. R. (2018). <b>The primary transcriptome of the fast-growing cyanobacterium <i>Synechococcus elongatus</i> UTEX 2973</b>. <i>Biotechnology for Biofuels</i>, <i>11</i>(1), 218.<br><br>
DOI: 10.6084/m9.figshare.5711977
title: Supplementary Material for: RegisPt: Registry of Registries in Portugal – Design, Data Model, and Functionalities

description: <b><i>Introduction:</i></b> The number and quality of existing patient registries are not known in Portugal. In order to improve the knowledge regarding this issue, an interactive tool (RegisPt) was developed to identify and characterize all available patient registries in our country. This article aims to describe the RegisPt design, data model, and due functionalities. <b><i>Methods:</i></b> RegisPt was developed in Microsoft Office Access 2010 and all variables definitions were done according to standardized international classifications. A review of the available literature and web resources was performed in order to identify all relevant patient registries. <b><i>Results:</i></b> The RegisPt platform is divided into 5 core modules containing comprehensive information from each patient registry (general data, registry design, characterization, effectiveness, and publications). Effectiveness is of utmost importance for health technology assessment and is divided into 2 sections: the exposure (health care service, pharmaceutical drugs, and medical devices) and the outcomes (safety, clinical, and economic). The RegisPt platform allows adding and editing registries as well as consulting all available registries in an interactive and user-friendly way, using a preferred query (e.g., registry name, institution, and therapeutic area). About 50 patient registries were identified and characterized in Portugal in accordance with the patient registry definition of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). <b><i>Discussion:</i></b> The RegisPt is a first step to better understand and use the available resources for health research in Portugal. RegisPt can promote collaboration between researchers and registry owners and encourage the efficient use of resources and may improve the access to registries. This project may also be useful to identify therapeutic areas still lacking patient registries and to optimize existing ones in the country, by comparing registry design, quality, and functional strategies. In the future, this valuable platform may be particularly relevant for researchers and authorities aiming to carry out health technology assessment.
DOI: 10.6084/m9.figshare.5711971
title: Dutch-Flemish PROMIS Physical Function dataset physical therapy patients PLOS One

description: Dataset for manuscript: <br><b>Psychometric Properties of the PROMIS Physical Function Item Bank in Patients Receiving Physical Therapy</b> <br>
DOI: 10.6084/m9.figshare.5711971.v1
title: Dutch-Flemish PROMIS Physical Function dataset physical therapy patients PLOS One

description: Dataset for manuscript: <br><b>Psychometric Properties of the PROMIS Physical Function Item Bank in Patients Receiving Physical Therapy</b> <br>
DOI: 10.6084/m9.figshare.5711965
title: Supplementary Material for: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus

description: <b><i>Background:</i></b> Pruritus is a distressing hallmark of the uremic condition, affecting approximately 60% of hemodialysis patients. Abnormal endogenous opioid ligand activity at μ and κ-opioid receptors has been postulated as a mechanism in uremic pruritus. Nalbuphine is a μ-opioid antagonist and κ-opioid agonist. <b><i>Methods:</i></b> In this multicenter, randomized, double-blind, placebo-controlled trial, 373 hemodialysis patients with moderate or severe uremic pruritus were randomized in a 1: 1:1 ratio to nalbuphine extended-release tablets 120 mg (NAL 120), 60 mg (NAL 60), or placebo and treated for 8 weeks. Three hundred seventy-one were analyzed for efficacy. The primary endpoint was the change from baseline to treatment weeks 7 and 8 in itching intensity on a Numerical Rating Scale (NRS, 0 [no itching]; 10 [worst possible itching]) using an intent-to-treat approach. The aim was to evaluate the safety and antipruritic efficacy of NAL. <b><i>Results:</i></b> The mean duration of itching was 3.2 years. From a baseline NRS of 6.9 (1.5), the mean NRS declined by 3.5 (2.4) and by 2.8 (2.2) in NAL 120 mg and the placebo groups, respectively (<i>p</i> = 0.017). There was no evidence of tolerance. A trend for less sleep disruption due to itching (<i>p</i> = 0.062, NAL 120 vs. placebo) was also observed. There were no significant differences between NAL 60 vs. placebo. Serious adverse events occurred in 6.7, 12.7, and 15.4% in the NAL 120, NAL 60, and placebo groups respectively. <b><i>Conclusions:</i></b> In this largest-to-date randomized controlled trial in uremic pruritus, NAL 120 durably and significantly reduced the itching intensity among hemodialysis patients.
DOI: 10.6084/m9.figshare.5711965.v1
title: Supplementary Material for: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus

description: <b><i>Background:</i></b> Pruritus is a distressing hallmark of the uremic condition, affecting approximately 60% of hemodialysis patients. Abnormal endogenous opioid ligand activity at μ and κ-opioid receptors has been postulated as a mechanism in uremic pruritus. Nalbuphine is a μ-opioid antagonist and κ-opioid agonist. <b><i>Methods:</i></b> In this multicenter, randomized, double-blind, placebo-controlled trial, 373 hemodialysis patients with moderate or severe uremic pruritus were randomized in a 1: 1:1 ratio to nalbuphine extended-release tablets 120 mg (NAL 120), 60 mg (NAL 60), or placebo and treated for 8 weeks. Three hundred seventy-one were analyzed for efficacy. The primary endpoint was the change from baseline to treatment weeks 7 and 8 in itching intensity on a Numerical Rating Scale (NRS, 0 [no itching]; 10 [worst possible itching]) using an intent-to-treat approach. The aim was to evaluate the safety and antipruritic efficacy of NAL. <b><i>Results:</i></b> The mean duration of itching was 3.2 years. From a baseline NRS of 6.9 (1.5), the mean NRS declined by 3.5 (2.4) and by 2.8 (2.2) in NAL 120 mg and the placebo groups, respectively (<i>p</i> = 0.017). There was no evidence of tolerance. A trend for less sleep disruption due to itching (<i>p</i> = 0.062, NAL 120 vs. placebo) was also observed. There were no significant differences between NAL 60 vs. placebo. Serious adverse events occurred in 6.7, 12.7, and 15.4% in the NAL 120, NAL 60, and placebo groups respectively. <b><i>Conclusions:</i></b> In this largest-to-date randomized controlled trial in uremic pruritus, NAL 120 durably and significantly reduced the itching intensity among hemodialysis patients.
DOI: 10.6084/m9.figshare.5711947
title: LGBTSTEMinar registration data

description: Raw numbers for registration at the UK LGBTSTEMinar conference in 2016 & 2017.<br>More information about the LGBTSTEMinar can be found here:https://lgbtstem.wordpress.com/lgbt-steminar/https://lgbtstem.wordpress.com/lgbt-steminar-2017/<br> <br>Registration has been analysed by Subject, Sexuality, Gender, Trans Identity and Institution/Workplace.<br>Figures showing results for these categories have also been included. Where &lt;5% of attendees identified with a subject these subjects have not been included in the figure, but can still be found in the raw data. <br>Data is released under a CC-BY license, however we would be keen to know if you are using this data (and help if we can), so please let us know if you are.
DOI: 10.6084/m9.figshare.5711947.v1
title: LGBTSTEMinar registration data

description: Raw numbers for registration at the UK LGBTSTEMinar conference in 2016 & 2017.<br>More information about the LGBTSTEMinar can be found here:https://lgbtstem.wordpress.com/lgbt-steminar/https://lgbtstem.wordpress.com/lgbt-steminar-2017/<br> <br>Registration has been analysed by Subject, Sexuality, Gender, Trans Identity and Institution/Workplace.<br>Figures showing results for these categories have also been included. Where &lt;5% of attendees identified with a subject these subjects have not been included in the figure, but can still be found in the raw data. <br>Data is released under a CC-BY license, however we would be keen to know if you are using this data (and help if we can), so please let us know if you are.
DOI: 10.6084/m9.figshare.5711929
title: GA3-clim

description: Precipitation data from the GA3-clim experiment<br>
DOI: 10.6084/m9.figshare.5711929.v1
title: GA3-clim

description: Precipitation data from the GA3-clim experiment<br>
DOI: 10.6084/m9.figshare.5711812
title: The geographical patterns of Chinese liquors during 1995–2004

description: Chinese liquors come from a variety of different regions in China. This diversity can be attributed to the difference in microorganisms, but also to the biophysical environment. The latter constitutes a significant basis for the fermentation of products, but has not been adequately understood. Using spatial statistics analysis, we studied the causes of regional differences of Chinese liquors in the perspective of climatic and socio-economic environment. Temporal changes in the density of Chinese liquor manufacturers in each prefecture-level administrative unit from1995 to 2004 revealed no changes in spatio-temporal distribution patterns of Chinese liquors. Most manufacturers were distributed in moderate climatic regions in both developed areas and less developed areas. Socio-economic factors had a significantly positive impact on the development of the Chinese liquor industry, while the climatic environment plays a crucial role in determining their difference a regional scale. Overall, this study provided scientific evidence for the importance of the biophysical environments, especially climate, to determine the geographical patterns of fermentation products.
DOI: 10.6084/m9.figshare.5711812.v1
title: The geographical patterns of Chinese liquors during 1995–2004

description: Chinese liquors come from a variety of different regions in China. This diversity can be attributed to the difference in microorganisms, but also to the biophysical environment. The latter constitutes a significant basis for the fermentation of products, but has not been adequately understood. Using spatial statistics analysis, we studied the causes of regional differences of Chinese liquors in the perspective of climatic and socio-economic environment. Temporal changes in the density of Chinese liquor manufacturers in each prefecture-level administrative unit from1995 to 2004 revealed no changes in spatio-temporal distribution patterns of Chinese liquors. Most manufacturers were distributed in moderate climatic regions in both developed areas and less developed areas. Socio-economic factors had a significantly positive impact on the development of the Chinese liquor industry, while the climatic environment plays a crucial role in determining their difference a regional scale. Overall, this study provided scientific evidence for the importance of the biophysical environments, especially climate, to determine the geographical patterns of fermentation products.
DOI: 10.6084/m9.figshare.5711695
title: GA3-31d

description: Precipitation data for the GA3-31d experiment<br>
DOI: 10.6084/m9.figshare.5711695.v1
title: GA3-31d

description: Precipitation data for the GA3-31d experiment<br>
DOI: 10.6084/m9.figshare.5711683
title: Whippet_analysis_scripts

description: Analysis scripts and data files to accompany Sterne-Weiler et al. paper
DOI: 10.6084/m9.figshare.5711683.v1
title: Whippet_analysis_scripts

description: Analysis scripts and data files to accompany Sterne-Weiler et al. paper
DOI: 10.6084/m9.figshare.5711683.v2
title: Whippet_analysis_scripts

description: Analysis scripts and data files to accompany Sterne-Weiler et al. paper
DOI: 10.6084/m9.figshare.5711683.v3
title: Whippet_analysis_scripts

description: Analysis scripts and data files to accompany Sterne-Weiler et al. paper